BlackRock Inc. Increases Stake in Athenex Inc (ATNX)

BlackRock Inc. increased its holdings in Athenex Inc (NASDAQ:ATNX) by 0.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,616,333 shares of the company’s stock after acquiring an additional 33,755 shares during the quarter. BlackRock Inc. owned approximately 5.41% of Athenex worth $45,892,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ATNX. Tower Research Capital LLC TRC acquired a new stake in Athenex in the third quarter valued at about $146,000. Prudential Financial Inc. purchased a new stake in Athenex in the 4th quarter valued at approximately $147,000. KCS Wealth Advisory boosted its holdings in Athenex by 8.9% in the 4th quarter. KCS Wealth Advisory now owns 12,182 shares of the company’s stock valued at $155,000 after purchasing an additional 1,000 shares in the last quarter. Man Group plc acquired a new position in Athenex during the 3rd quarter worth approximately $201,000. Finally, MetLife Investment Advisors LLC increased its position in Athenex by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 31,296 shares of the company’s stock worth $486,000 after purchasing an additional 11,125 shares during the period. 31.75% of the stock is currently owned by institutional investors and hedge funds.

ATNX stock opened at $11.70 on Friday. Athenex Inc has a 52 week low of $9.83 and a 52 week high of $20.90. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.31 and a quick ratio of 2.75.

Athenex (NASDAQ:ATNX) last issued its earnings results on Monday, March 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.21). Athenex had a negative net margin of 131.81% and a negative return on equity of 66.23%. The company had revenue of $21.27 million during the quarter. On average, analysts expect that Athenex Inc will post -1.75 earnings per share for the current fiscal year.

A number of research firms recently weighed in on ATNX. BidaskClub downgraded Athenex from a “hold” rating to a “sell” rating in a research note on Saturday, December 8th. Royal Bank of Canada reiterated an “outperform” rating on shares of Athenex in a research report on Tuesday, March 12th. Finally, SunTrust Banks initiated coverage on shares of Athenex in a research report on Friday, March 29th. They set a “buy” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $20.00.

In other news, CEO Johnson Yiu Nam Lau acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was purchased at an average cost of $11.78 per share, with a total value of $117,800.00. Following the purchase, the chief executive officer now directly owns 2,917,422 shares of the company’s stock, valued at approximately $34,367,231.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sheldon Trainor-Degirolamo sold 45,915 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $11.77, for a total value of $540,419.55. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $47,080. The disclosure for this sale can be found here. In the last three months, insiders have bought 57,500 shares of company stock worth $696,090 and have sold 132,240 shares worth $1,559,044. 29.50% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Increases Stake in Athenex Inc (ATNX)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Recommended Story: Why are percentage decliners important?

Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with's FREE daily email newsletter.